Sarepta Therapeutics | SRPT - Bruttoergebnis Vom Umsatz

Aktienkurs
21.18
Täglich Wechseln
-1.05 -4.72%
Monatlich
20.51%
Jährlich
-58.50%
Q2 Prognose
20.60




Bruttoergebnis Vom Umsatz Veränderung Datum
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Capricor Therapeutics 11.13M 8.87M 2024-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Incyte USD 1.39B 118.68M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
Moderna USD 226M 583M 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Tectonic Therapeutic USD 0 0 2025-03
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12